| Similar Articles |
|---|
 |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile.   |
The Motley Fool
August 29, 2011
Brian Orelli |
We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply. |
The Motley Fool
May 3, 2011
Brian Orelli |
Brakes Are Off at Dendreon Ramping up sales, one month at a time. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
March 11, 2011
Brian Orelli |
Sales Can Quadruple, More to Come Dendreon is still supply-constrained, but less than before. |
The Motley Fool
August 4, 2011
Brian Orelli |
Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse? |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
January 7, 2011
Brian Orelli |
Dendreon Heads Across the Pond A pathway to Provenge approval in the EU. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
August 8, 2011
Luke Timmerman |
Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Is Dendreon doomed? |
The Motley Fool
June 30, 2011
Brian Orelli |
Dendreon Increases Potential Output, More to Come Los Angeles plant is approved. |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
The Motley Fool
February 7, 2011
Brian Orelli |
Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet. |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge. |
The Motley Fool
January 5, 2012
David Williamson |
Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%. |
The Motley Fool
August 31, 2010
Brian Orelli |
What Is Dendreon Worth? Now that's a good question, isn't it? |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
The Motley Fool
October 11, 2010
Brian Orelli |
A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer. |
The Motley Fool
September 28, 2010
Brian Orelli |
It's Up! It's Down! It's Dendreon! The joys of biotech. |
The Motley Fool
August 4, 2010
Brian Orelli |
Dendreon Doubles Up The biotech enjoys twice as much revenue month over month. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
August 4, 2010
Luke Timmerman |
Dendreon Conference Call Notebook: The Tale of a Provenge Launch Ramp-Up What's working for Dendreon? How is its groundbreaking prostate cancer drug performing in its first few months on the market? |
The Motley Fool
April 5, 2010
Brian Orelli |
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks. |
The Motley Fool
September 25, 2009
Brian Orelli |
Dendreon Struts Its Stuff Like a peacock without any FDA-approved feathers. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
March 28, 2011
Brian Orelli |
Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news. |
The Motley Fool
June 18, 2009
Daniel Harrison |
Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains. |
The Motley Fool
July 1, 2011
Brian Orelli |
Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
The Motley Fool
November 11, 2010
Brian Orelli |
Moderate Results, Moderate Rally for Dendreon Sometimes good enough really is good enough. |
The Motley Fool
June 19, 2009
Brian Orelli |
Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
July 1, 2011
Luke Timmerman |
Dendreon Sways Medicare to Pay for Prostate Cancer Drug The decision by Medicare is no surprise, but it does conclude a period of uncertainty about insurance reimbursement for its lone marketed product. |
The Motley Fool
July 1, 2010
Brian Orelli |
Is Dendreon's Provenge in Trouble Before It Starts? Not! The Centers for Medicare & Medicaid Services questions the coverage of Provenge. |
The Motley Fool
November 2, 2011
David Williamson |
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock. |
The Motley Fool
August 9, 2010
Brian Orelli |
Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble." |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
October 31, 2011
Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
June 29, 2011
Brian Orelli |
4 Immunotherapies to Watch Just don't go all-in. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
